Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cti Biopharm Corp (NQ: CTIC )

2.970 USD +0.010 (+0.34%)
Official Closing Price Updated: 4:00 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Cti Biopharm Corp

< Previous 1 2 Next >
CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar. 4
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST. The conference will be held in a... 
From PR Newswire
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new employees with a grant date of February 24, 2021, as... 
From PR Newswire
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of February 10, 2021, as equity... 
From PR Newswire
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of January 28, 2021, as equity... 
From PR Newswire
CTI BioPharma to Present at The JMP Securities Hematology Summit on Tuesday, Dec. 15
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual... 
From PR Newswire
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting
Results from Investigator-sponsored Phase 1/2 Study of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Demonstrate Encouraging Efficacy and Safety Profile when Combining... 
From PR Newswire
CTI BioPharma Announces Publication of Article Highlighting Pacritinib Data from the PAC203 Phase 2 Study in Myelofibrosis in Blood Advances
CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Determining the Recommended Dose of Pacritinib:... 
From PR Newswire
CTI BioPharma Reports Third Quarter 2020 Financial Results
- Rolling NDA Submission for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia Initiated in October - 
From PR Newswire
CTI BioPharma Announces Oral Presentation at the 62nd American Society of Hematology Meeting
CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of... 
From PR Newswire
CTI BioPharma to Report Third Quarter 2020 Financial Results on November 10, 2020
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S.... 
From PR Newswire
Thinking about buying stock in Pfizer, Delta Air Lines, Norwegian Cruise Line, CTI BioPharma, or Honeywell?
InvestorsObserver issues critical PriceWatch Alerts for PFE, DAL, NCLH, CTIC, and HON. 
From PR Newswire
Thinking about buying stock in Enlivex Therapeutics, Vaxart, CTI BioPharma, Workhorse Group, or Electrameccanica Vehicles?
InvestorsObserver issues critical PriceWatch Alerts for ENLV, VXRT, CTIC, WKHS, and SOLO. 
From PR Newswire
CTI BioPharma Initiates Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
- Completion of Submission Expected in First Quarter 2021 - 
From PR Newswire
Thinking about buying stock in Trevena, CTI BioPharma, Phunware, FuelCell Energy, or YRC Worldwide?
InvestorsObserver issues critical PriceWatch Alerts for TRVN, CTIC, PHUN, FCEL, and YRCW. 
From PR Newswire
CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia
- Company to Proceed with Rolling NDA Submission following Recent Pre-NDA Meeting with FDA - 
From PR Newswire
CTI BioPharma Reports Second Quarter 2020 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020. 
From PR Newswire
Modernized Approaches to Patient Monitoring Ease Pressure on Medical Systems
FinancialBuzz.com News Commentary 
From PR Newswire
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
- Company Expects to Report Topline Data by the End of 2020 - 
From PR Newswire
CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be... 
From PR Newswire
CTI BioPharma Reports First Quarter 2020 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2020. 
From PR Newswire
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19
- Study to Determine Whether Pacritinib Can Prevent Progression to Acute Respiratory Distress Syndrome and Mechanical Ventilation - 
From PR Newswire
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held... 
From PR Newswire
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019. 
From PR Newswire
CTI BioPharma Announces Closing of Rights Offering
CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, CTI BioPharma sold and issued an aggregate of... 
From PR Newswire
CTI BioPharma Announces Commencement of Rights Offering
CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights... 
From PR Newswire
CTI BioPharma Announces Proposed Rights Offering
Rights Offering will be Available to All Stockholders of Record on February 13, 2020 
From PR Newswire
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia
PACIFICA Trial Protocol Amended to Allow for Primary Analysis of Spleen Volume Reduction (SVR) Rates on 168 Patients 
From PR Newswire
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting
Results from PAC203 Demonstrate Pacritinib 200 mg Twice-Daily (BID) is Well Tolerated with Clinical Benefit in the Highest Risk Myelofibrosis Patient Population 
From PR Newswire
CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting
CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American Society of Hematology... 
From PR Newswire
CTI BioPharma Reports Third Quarter 2019 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019. 
From PR Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.